B
Bull
Bull · 25%MAZE
$21.54
Scenario price
$27.530
+0.050 (+0.18%)At close
Loading chart…
- High
- 27.890
- Open
- 27.500
- VWAP
- 27.38
- Volume
- 1.02M
- Mkt Cap
- —
- Low
- 26.720
- Amount
- 27.89M
- EV/EBITDA, TTM
- -24.23
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
AI analysis of Maze Therapeutics Inc (MAZE)
BuyMaze Therapeutics is a good buy right now, as it is currently priced at $27.53, with a forward P/E of 8.53, indicating potential undervaluation. The RSI is at 61.38, suggesting bullish momentum, and analysts project significant upside with targets of $50 and $64. However, the main risk is the recent insider stock sale by the Chief Medical Officer, which may indicate concerns about the company's future prospects.
Valuation Metrics
The current forward P/E ratio for Maze Therapeutics Inc (MAZE) is 8.53, compared to its 5-year average forward P/E of 1.42.
Alphio AI Price Scenarios for MAZE
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding MAZE
Events Timeline
News
MAZE FAQ — answered by Alphio AI
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target. It operates in the Healthcare sector.
Maze Therapeutics is a good buy right now, as it is currently priced at $27.53, with a forward P/E of 8.53, indicating potential undervaluation. The RSI is at 61.38, suggesting bullish momentum, and analysts project significant upside with targets of $50 and $64. However, the main risk is the recent insider stock sale by the Chief Medical Officer, which may indicate concerns about the company's future prospects.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.